Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.55B 3.97B 3.74B 3.4B 6.38B 436B 6.39B 44.75B 17.25B 222B 17.09B 16.71B 717B	P/E 2024	-51.1x	P/E 2025	-162x
Enterprise Value	4.7B 4.1B 3.86B 3.51B 6.59B 450B 6.6B 46.21B 17.81B 229B 17.65B 17.26B 740B	EV / Sales 2024	5.69x	EV / Sales 2025	7.18x
Free-Float	99.31%	Yield 2024 *	-	Yield 2025	-

06/05	BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says	MT
29/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Global BMI Index	CI
29/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P TMI Index	CI
29/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000 Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Growth-Dynamic Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Growth-Dynamic Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Dynamic Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Index	CI

06/05	BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says	MT
22/01	Jefferies Downgrades Amicus Therapeutics to Hold From Buy, Adjusts Price Target to $14.50 From $16	MT
29/12	Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17	MT
22/12	TD Cowen Downgrades Amicus Therapeutics to Hold From Buy, Adjusts PT to $14.50 From $20	MT
20/12	Top Midday Gainers	MT

09/03	US Senate Probes FDA Bureaucracy vs. Innovation	AQ
24/02	Amicus Therapeutics: Q4 Earnings Snapshot	AQ
21/02	Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates	AQ
04/02	Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026	AQ
10/01	Amicus Therapeutics : Legend (1)	PU

20/02	BB Biotech bestätigt Gewinn 2025
20/12	Wall Street optimistisch het weekend in
20/12	MÄRKTE USA/Zinssenkungshoffnung stützen Börse - Oracle fest
20/12	MÄRKTE USA/Börsen von Zinssenkungshoffnung gestützt - Oracle fest
20/12	MÄRKTE USA/Positive Stimmung hält - Oracle mit TikTok-Deal fest

Amicus Therapeutics Stock Nasdaq

Stocks

Biotechnology & Medical Research

Valuation: Amicus Therapeutics

Latest news: Amicus Therapeutics

Last Transcript: Amicus Therapeutics

Analysts' recommendations: Amicus Therapeutics

Press Releases: Amicus Therapeutics

News in other languages: Amicus Therapeutics

Quotes and Performance

Managers and Directors: Amicus Therapeutics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICUS THERAPEUTICS	+1.57%	+1.65%	-	-	4.55B
LONZA GROUP AG	+0.59%	+2.73%	+1.03%	+28.74%	46.28B
IQVIA HOLDINGS INC.	+1.30%	+1.58%	+44.15%	+35.50%	43.85B
REVOLUTION MEDICINES, INC.	+0.95%	-6.02%	+342.72%	+532.41%	40.93B
BEONE MEDICINES AG	+4.23%	+3.35%	+9.35%	+94.73%	39.89B
CELLTRION, INC.	+1.11%	+1.45%	+11.52%	+45.96%	29.5B
MEDPACE HOLDINGS, INC.	+1.94%	+4.84%	+25.19%	+159.21%	17.09B
ASCENDIS PHARMA A/S	+0.37%	-10.32%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+2.12%	+8.18%	+24.78%	+41.21%	15.22B
TEMPUS AI, INC.	+0.24%	+25.43%	-11.57%	-	14.05B
Average	+1.43%	+3.23%	+55.90%	+133.97%	29.15B
Weighted average by Cap.	+1.51%	+1.71%	+70.37%	+142.46%

	2024	2025
Net sales	528M 461M 434M 395M 741M 50.61B 742M 5.2B 2B 25.78B 1.98B 1.94B 83.2B	634M 553M 521M 474M 889M 60.76B 890M 6.24B 2.4B 30.95B 2.38B 2.33B 99.88B
Net income	-56.11M -48.92M -46.07M -41.96M -78.67M -5.38B -78.77M -552M -213M -2.74B -211M -206M -8.84B	-27.11M -23.64M -22.26M -20.27M -38.01M -2.6B -38.06M -267M -103M -1.32B -102M -99.58M -4.27B
Net Debt	194M 169M 159M 145M 272M 18.56B 272M 1.9B 734M 9.45B 728M 711M 30.5B	149M 130M 122M 111M 209M 14.26B 209M 1.46B 564M 7.26B 559M 547M 23.44B